风湿免疫

订阅

MedSci主页 / 所有栏目 / 风湿免疫

风湿科医生必备：ANA谱（抗核抗体谱）各项指标临床检测意义

2022-04-09 网络 网络

ANA风湿免疫抗核抗体抗核抗体检测
关注

ANA谱（抗核抗体谱）各项指标临床检测意义

ANA谱（抗核抗体谱）各项指标临床检测意义

欧蒙印迹法

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2185392, encodeId=72d2218539282, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24783615381, createdName=13360100m25暂无昵称, createdTime=Fri Feb 02 10:40:18 CST 2024, time=2024-02-02, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2041190, encodeId=f45e2041190f1, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 24 10:33:15 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633630, encodeId=03cf163363052, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Jan 21 12:33:15 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585647, encodeId=4dd2158564e0c, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Mon Apr 11 10:33:15 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209920, encodeId=23191209920d6, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Apr 09 22:51:31 CST 2022, time=2022-04-09, status=1, ipAttribution=)]
    2024-02-02 13360100m25暂无昵称 来自河南省

    收藏学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2185392, encodeId=72d2218539282, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24783615381, createdName=13360100m25暂无昵称, createdTime=Fri Feb 02 10:40:18 CST 2024, time=2024-02-02, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2041190, encodeId=f45e2041190f1, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 24 10:33:15 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633630, encodeId=03cf163363052, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Jan 21 12:33:15 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585647, encodeId=4dd2158564e0c, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Mon Apr 11 10:33:15 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209920, encodeId=23191209920d6, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Apr 09 22:51:31 CST 2022, time=2022-04-09, status=1, ipAttribution=)]
    2022-07-24 heli0118

    #抗体谱#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2185392, encodeId=72d2218539282, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24783615381, createdName=13360100m25暂无昵称, createdTime=Fri Feb 02 10:40:18 CST 2024, time=2024-02-02, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2041190, encodeId=f45e2041190f1, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 24 10:33:15 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633630, encodeId=03cf163363052, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Jan 21 12:33:15 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585647, encodeId=4dd2158564e0c, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Mon Apr 11 10:33:15 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209920, encodeId=23191209920d6, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Apr 09 22:51:31 CST 2022, time=2022-04-09, status=1, ipAttribution=)]
    2023-01-21 AspirantSuo

    #ANA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2185392, encodeId=72d2218539282, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24783615381, createdName=13360100m25暂无昵称, createdTime=Fri Feb 02 10:40:18 CST 2024, time=2024-02-02, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2041190, encodeId=f45e2041190f1, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 24 10:33:15 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633630, encodeId=03cf163363052, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Jan 21 12:33:15 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585647, encodeId=4dd2158564e0c, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Mon Apr 11 10:33:15 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209920, encodeId=23191209920d6, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Apr 09 22:51:31 CST 2022, time=2022-04-09, status=1, ipAttribution=)]
    2022-04-11 mhzhuang@stu.e

    #抗核抗体#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2185392, encodeId=72d2218539282, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24783615381, createdName=13360100m25暂无昵称, createdTime=Fri Feb 02 10:40:18 CST 2024, time=2024-02-02, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2041190, encodeId=f45e2041190f1, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 24 10:33:15 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633630, encodeId=03cf163363052, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Jan 21 12:33:15 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585647, encodeId=4dd2158564e0c, content=<a href='/topic/show?id=57b35536958' target=_blank style='color:#2F92EE;'>#抗核抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55369, encryptionId=57b35536958, topicName=抗核抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43717252607, createdName=mhzhuang@stu.e, createdTime=Mon Apr 11 10:33:15 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209920, encodeId=23191209920d6, content=收藏学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e845489837, createdName=金朝岁月, createdTime=Sat Apr 09 22:51:31 CST 2022, time=2022-04-09, status=1, ipAttribution=)]
    2022-04-09 金朝岁月

    收藏学习

    0

相关资讯

Arthritis Rheumatol：美国人群中抗核抗体的患病率升高

近年来，美国ANA的患病率明显升高。